Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Personalized navigation may boost cancer screening in high-risk communities

NCT ID NCT07676383

Prevention Sponsor: Hunan Cancer Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 30, 2026 · Last updated Sep 18, 2026 · Updated 4 times

Summary

This study tests whether giving people a personalized report about their cancer risk and screening options helps them complete recommended cancer tests. Adults aged 45 to 74 who are at high risk for lung, breast, colorectal, upper gastrointestinal, or liver cancer are invited to take part. Some receive a tailored navigation report with step-by-step guidance, while others get general health education or no active promotion. The goal is to see if personalized support increases screening participation and improves early detection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
precision navigation intervention (personalized report and staff explanation)
What this could lead to
If effective, this approach could increase cancer screening rates in high-risk communities, leading to earlier detection and better outcomes.
What could go wrong
This is a behavioral intervention study, not a drug trial. Results may vary by community and may not generalize beyond the specific program in China.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 74 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged 45 to 74 years. 2. Permanent resident of a participating community, defined as having lived in the community for at least 6 months during the past 12 months. 3. Participating in the urban cancer screening program. 4. Identified by the program risk assessment questionnaire as being at high risk for at least one of the following cancers: lung cancer, breast cancer, colorectal cancer, upper gastrointestinal cancer, or liver cancer. 5. Has not yet completed the corresponding free clinical screening test for the high-risk cancer type or types. 6. Able to complete electronic questionnaires and read intervention materials independently or with assistance. Paper materials and staff explanation will be provided for participants who do not use smartphones. 7. Able and willing to provide written informed consent. Exclusion Criteria: 1. Previously diagnosed with any of the target cancers, including lung cancer, breast cancer, colorectal cancer, upper gastrointestinal cancer, or liver cancer. 2. Severe cognitive impairment, severe mental illness, or other conditions that prevent the participant from receiving the intervention or completing study questionnaires. 3. Planning to be away from the community for a long period during the next 6 months, defined as cumulative absence of more than 3 months. 4. Currently participating in another interventional study that may affect cancer screening behavior.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm colorectal cancer colorectal neoplasm digestive system cancer digestive system neoplasm gastroesophageal cancer liver cancer Liver Neoplasms lung cancer lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Cancer screening Colorectal cancer Liver cancer Lung cancer Upper gastrointestinal cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Huaihua Central Hospital (Huaihua Cancer Hospital)

    RECRUITING

    Huaihua, Hunan, China

  • Shaoyang Hospital of Traditional Chinese Medicine

    RECRUITING

    Shaoyang, Hunan, China

  • Yongzhou Central Hospital

    RECRUITING

    Yongzhou, Hunan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.